SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Capricor Therapeutics, Inc. is a clinical-stage biotechnology company, which focuses on the development of transformative cell and exosome-based therapeutics for treating Duchenne muscular dystrophy (“DMD”), a rare form of muscular dystrophy which results in muscle degeneration and premature death, and other diseases with unmet medical needs. Its product candidate consists of CAP-1002, Engineered Exosomes, CAP-2003, and Exosome-Based Vaccine. The company was founded on June 17, 1996 and is headquartered in San Diego, CA.

Capricor Therapeutics Inc

Attention centers on the FDAs upcoming decision on Capricors deramiocel for Duchenne muscular dystrophy, with traders citing the amended upper-limb data, rare-disease policy discussions and recent launch-related hiring as reasons for optimism. Others caution that approval is uncertain given the prior negative review and continuing questions about the evidence.

Precigen, Inc. is a biotechnology company, which engages in the research and development of synthetic biology technologies. It operates through the Biopharmaceuticals and Exemplar segments. The company was founded by Thomas David Reed in 1998 and is headquartered in Germantown, MD.

Precigen Inc

Precigens strong quarterly results and rapid PAPZIMEOS commercial uptake are driving attention, with traders highlighting the companys return to profitability and potential for further growth. The upbeat reaction is accompanied by short-squeeze speculation and interest in upcoming PRGN-2009 data and European expansion.

TG Therapeutics, Inc. engages in the acquisition, development, and commercialization of novel treatments for B-cell malignancies and autoimmune diseases. Its product pipeline includes TG-1501, TG-1701, Ublituximab, and Umbralisib. The company was founded by Michael Sean Weiss and Laurence H. Shaw on May 18, 1993 and is headquartered in Morrisville, NC.

TG Therapeutics Inc

A run to a 52-week high has traders positioning around the expected Q3 earnings report, with BRIUMVIs sales growth supporting optimism. Buyout rumors and heavy short interest are fueling squeeze speculation, though some traders see earnings expectationsnot a confirmed acquisitionas the main driver.

CorMedix, Inc. is a pharmaceutical and medical device company, which engages in the development and commercialization of therapeutic products for the prevention and treatment of diseases and conditions. The company was founded by Antony E. Pfaffle on July 28, 2006 and is headquartered in Berkeley Heights, NJ.

CorMedix Inc

DaVitas warning that DefenCaths post-TDAPA Medicare add-on could fall sharply after Q1 2027 has fueled concerns about pricing and CorMedix revenue amid a steep selloff. Traders dispute whether DaVitas preliminary outlook signals a broader reimbursement decline, pointing to CMSs published estimate, while others criticize management for not clarifying the potential impact.

SELLAS Life Sciences Group, Inc. is a clinical stage biopharmaceutical company, which engages in the development and commercialization of immunotherapeutic for cancer indications. Its product pipeline includes galinpepimut-S. The company was founded by Angelos M. Stergiou on April 3, 2006 and is headquartered in New York, NY.

SELLAS Life Sciences Group Inc

SELLASs Phase 3 REGAL leukemia trial reached its prespecified 80th death event, triggering final analysis and putting the GPS survival readout at the center of discussion. Traders are divided between optimism about a strong result and concerns about the control arm and trial design, while shares have come under pressure ahead of the binary catalyst.

AppLovin Corp. engages in the development and operation of a mobile marketing platform. It offers AppDiscovery, MAX, Adjust, and SparkLabs. Its software-based platform caters to mobile application developers to improve the marketing and monetization of applications. The company was founded by Andrew Karam, John Krystynak, and Adam Foroughi in 2011 and is headquartered in Palo Alto, CA.

Applovin Corp - Ordinary Shares - Class A

Applovin Corp

AppLovin is under pressure after a steep decline, with traders focused on analyst price-target cuts and uncertainty ahead of its earnings report, as well as concerns about digital-ad growth. Bulls argue the selloff is disconnected from the companys profitability and growth, while bears warn of more downside if results or guidance disappoint; some also point to broader tech-market weakness.

Invesco QQQ Trust Series 1 - Invesco QQQ Trust Series 1

A sharp technology and AI-linked selloffintensified by Intels weak outlook and concerns about returns on heavy AI investmentis driving attention to QQQ. Traders are split between warning of more downside and treating the drop as an oversold dip with potential for a rebound.

VanEck ETF Trust - VanEck Semiconductor ETF

VanEck Semiconductor ETF

SMH is under pressure amid a semiconductor and tech selloff, as traders question whether heavy AI infrastructure spending will generate adequate returns; weak Intel guidance and concerns about Amazons elevated capex are cited as contributing pressures. The community is divided between expecting a deeper unwind in the AI trade and seeing oversold conditions and technical support as possible grounds for a bounce.

Okta, Inc. engages in the provision of an identity management platform for enterprises. The firm operates through the following geographical segments: United States and International. Its products include single sign-on, multi-factor authentication, access gateway, API access management, authentication, adaptive MFA and lifecycle management. The company was founded by Todd McKinnon and J. Frederic Kerrest in 2009 and is headquartered in San Francisco, CA.

Okta Inc - Ordinary Shares - Class A

Okta Inc

Oktas strong quarterly results and raised outlook, alongside expectations that AI agents will increase demand for identity security, fueled a sharp rally. Traders are now debating whether the growth outlook justifies the valuation, with some taking profits or positioning for a pullback.

Regeneron Pharmaceuticals, Inc. is a biotechnology company, which engages in the discovery, invention, development, manufacture, and commercialization of medicines. Its product portfolio includes the following brands: Dupixent, Evkeeza, Eylea, Inmazeb, and Kevzara. The firm accelerates the traditional drug development process through its proprietary VelociSuite technologies such as VelocImmune, which uses unique genetically humanized mice to produce optimized fully human antibodies and bispecific antibodies. The company was founded by Alferd G. Gilman, Leonard S. Schleifer, George Damis Yancopoulos, and Eric M. Shooter on January 8, 1988, and is headquartered in Tarrytown, NY.

Regeneron Pharmaceuticals, Inc.

Regenerons stronger-than-expected third-quarter results, supported by growth in Eylea HD and Sanofi collaboration revenue from Dupixent, drove a sharp share-price gain. Traders largely celebrated the earnings beat and breakout, while some pointed to the upcoming cemdisiran decision as another potential catalyst.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

If You Invested $100 In Ubiquiti Stock 10 Years Ago, You Would Have This Much Today

Ubiquiti (NYSE:UI) has outperformed the market over the past 10 years by 13.92% on an annualized basis producing an average annual return of 27.48%. Currently, Ubiquiti has a market capitalization of $36.88 billion.read more...

Nokia's Q3 Earnings Beat Estimates on AI & Cloud Strength

NOK's Q3 2026 earnings beat estimates as revenues rise 10% and AI & Cloud sales surge 123%, fueled by robust IP Networks and Optical Networks demand.

Can Nokia's Latest Portfolio Move Strengthen Its AI Networking Focus?

NOK's planned ECE divestiture aims to sharpen its focus on AI networking as AI and Cloud revenue more than doubles and orders reach ???2.8 billion.

Can Ericsson's Latest 6G Milestone Strengthen Its Growth Outlook?

ERIC's first pre-standard 6G field call with Verizon in the 7 GHz band advances real-world testing as the company navigates uneven telecom spending and competition.

Comtech Telecommunications (CMTL) Reports Break-Even Earnings for Q4

Comtech (CMTL) delivered earnings and revenue surprises of +100.00% and -40.68%, respectively, for the quarter ended July 2026. Do the numbers hold clues to what lies ahead for the stock?

UI INVESTOR ALERT: Bronstein, Gewirtz and Grossman, LLC Announces an Investigation into Ubiquiti Inc. and Encourages Investors to Contact the Firm

UI INVESTOR ALERT: Bronstein, Gewirtz and Grossman, LLC Announces an Investigation into Ubiquiti Inc. and Encourages Investors to Contact the Firm UI INVESTOR ALERT: Bronstein, Gewirtz and Grossman, LLC Announces an Investigation into Ubiquiti Inc. and Encourages Investors to Contact the FirmPR...

Ericsson Wins Cellnex Poland 5G RAN Deal: More Upside Ahead?

ERIC secures a Cellnex Poland 5G RAN deal to modernize networks, boost coverage and efficiency, and expand its role in European 5G infrastructure.

JBL Q4 Earnings Beat Estimates on AI Infrastructure Strength

Jabil's Q4 earnings and revenues beat estimates as AI infrastructure demand surges, with FY27 growth expected to remain strong.

Ubiquiti Bets Big on UniFi Ecosystem: Should You Buy the Stock?

UI's expanding UniFi ecosystem, Enterprise Technology momentum and scalable operating model support growth, profitability and earnings expansion.

Zacks.com featured highlights include Match Group, monday.com, Ubiquiti and Semtech 

monday.com is gaining from AI adoption and larger customers, with revenue growth and rising AI ARR highlighting its expansion.

Ubiquiti, Inc. engages in the business of selling equipment and provision of related software platforms. It operates through the Enterprise Technology and Service Provider Technology product categories. The company was founded by Robert J. Pera in October 2003 and is headquartered in New York, NY.

Ubiquiti Inc

Why Did Ubiquiti Stock Surge 28% Today?

Equity

Bearish Sentiment

Ubiquiti Inc. (UI) disclosed a new stock repurchase program valued at up to $500 million and a 33% increase in its quarterly dividend to $0.80 from the previous $0.60 after it reported better-than-expected fourth quarter (Q4) earnings.The company’s revenue of $759.2 million and adjusted earnings per share (EPS) of $3.54, surpassed the analysts’ consensus estimate of $618 million and $2.23, respectively, as per Fiscal AI data.<a href="https://stocktwits.com/symbol/UI">Ubiquiti stock</a> traded over 28% higher on Friday afternoon. On Stocktwits, retail sentiment toward the stock jumped to ‘extremely bullish’ from ‘neutral’ territory the previous day. Message volume improved to ‘extremely high’ from ‘high’ levels in 24 hours.&nbsp;<figure class="image"><img style="aspect-ratio:931/106;" src="https://news.stocktwits-cdn.com/Screenshot_2025_08_22_140428_png_cfc2c60ebc.webp" alt="UI’s Sentiment Meter and Message Volume as of 01:45 p.m. ET on Aug.22, 2025 | Source: Stocktwits" width="931" height="106"><figcaption>UI’s Sentiment Meter and Message Volume as of 01:45 p.m. ET on Aug.22, 2025 | Source: Stocktwits</figcaption></figure>A Stocktwits user commended the company’s buyback announcement.&nbsp;<stembedurl>https://stocktwits.com/Costales/message/626213881</stembedurl>For the fiscal year 2025, Ubiquiti generated total revenue of $2.6 billion and an adjusted EPS of $10.96. The increased dividend payment is scheduled for September 8, to shareholders of record as of September 2. The company indicated plans to maintain this $0.80 per share dividend throughout fiscal 2026.&nbsp;Ubiquiti received a price target boost from Barclays, which increased its target to $299, up from $247, while maintaining an ‘Underweight’ rating on the stock, as per TheFly.The adjustment comes in response to stronger-than-anticipated performance in Ubiquiti’s Enterprise segment, and strong performance in overall revenue and profit margins. Barclays said that it previously underestimated how cyclical the Enterprise business could be, and now anticipates that this dynamic may persist into fiscal year 2026.&nbsp;Ubiquiti stock has gained over 51% year-to-date and over 1845 in the last 12 months.&nbsp;Also See:&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/apple-considers-possibility-of-using-gemini-ai/chsZ9STRdKI">Apple Considers Possibility Of Using Gemini AI To Power Next-Gen Siri: Report</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

In this photo illustration, the Ubiquiti logo is seen displayed on a smartphone screen.

The company announced a new stock repurchase program valued at up to $500 million and a 33% increase in its quarterly dividend.

Hold rates steady

Cut 25 bps

Hike 25 bps

Fed decision day is here - Kevin Warsh chairs his first FOMC meeting with markets pricing a hold at 3.50%-3.75% but watching for a hawkish shift. Vote on what you expect to be decided today, then drop your prediction for the first rate cut or hike in the comments.

What do you expect the Fed to decide at its FOMC meeting today? 
 
Drop a comment with when you expect the first cut/hike to be.

Current Price	$563.81
Prev Close	$606.71
Open	$599.87
Dividend Yield	0.60%
50-Day Moving Average	$589.33
Beta	1.51
Avg. Volume	154,548.37
PE Ratio	38.27

52-Week High	$1,099.99
52-Week Low	$500.23
Market Capitalization	$36.71B
EPS (Annual)	$15.85
Price to Book	25.50
Revenue Per Employee	$1.8M

Feed

News

Sentiment

Earnings

Fundamentals

Info

UI Fundamentals